Solvay Pharmaceuticals, Gmbh

Kali-chemie Pharma Gmbh

Ulf Preuschoff

Samuel David

Jochen Antel

Holger Sann

Christian Eeckhout

Ivan Ban

Daniel Jasserand

Michael Weske

Michael Wurl

Johannes Hebebrand

Reiner Muller-Peddinghaus

Reinhard Brueckner

Dagmar Hoeltje

Insa Hell

Marie-Odile Christen

Dania B Reiche

Rainer Walenta

Timo Heinrich

Peter Eickelmann

Klaus-Ullrich Wolf

Werner Benson

Bernd Junker

Ineke Van Wijngaarden

Emil Finner

Hermann Kraehling

Reinhard Brückner

Bartholomeus J Van Steen

Uwe Schön

Michael Reggelin

Karin Van Charldorp

Peter C Gregory

Ton Hulkenberg

Martin Tulp

Matthias Mentzel

Herman Kraehling

4-substituted 1-amidomethylcarbonyl-piperidine compounds having motilin-agonistic properties and their acid addition salts, pharmaceutical compositions containing these compounds, processes and intermediate products for the preparation of these compounds, and methods of treatment utilizing these compounds.

1-amidomethylcarbonyl-piperidine compounds, methods and intermediate products for the production thereof and pharmaceutical formulations containing said compounds

A method for the discovery of compounds suitable for the treatment and/or prophylaxis of obesity, in which the ability of the test compounds to inhibit de novo lipogenesis in mammals and/or man is determined. The use of compounds which are capable of inhibiting de novo lipogenesis in mammals, and which are substantially free of effects directed towards the CNS, for the preparation of pharmaceutical compositions for the treatment and/or prophylaxis of obesity, as well as for the treatment and/or inhibition of obesity, are also described.

Method of preparing pharmaceutical compositions

The invention relates to a group of hydronopol derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel hydronopol derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1) wherein the symbols have the meanings as given in the description.

Hydronopol derivatives as agonists on human ORL1 receptors

Method of treating or inhibiting obesity

Method of identifying compounds suitable for treatment and/or prophylaxis of obesity

A method for stereochemically controlled production of azacyclic compounds of general formula (I)in which the substituents have the meanings given in the specification. The invention also relates to intermediate products of this method and to novel azacyclenes.

Method for stereochemically controlled production of isomerically pure highly substituted azacyclic compounds

1-&lsqb;1-(hetero)aryl-1-perhydroxyalkylmethyl&rsqb;-piperazine compounds, process for their preparation and pharmaceutical compositions containing them

Ring-contracted N-demethyl-N-isopropyl-erythromycin-A derivatives having a modified side chain and gastrointestinally effective motilin-agonistic properties and the preparation thereof are described.

11-acetyl-12,13-dioxabicyclo[8.2.1]-tridecenone derivatives, processes

Ring-contracted N-demethyl-N-isopropyl-erythromycin-A-spiroacetal compounds corresponding to formula I ##STR1## having gastrointestinally effective motilin-agonistic properties and the preparation thereof.

10, 13, 15-trioxatricyclo �9.2.1.1..sup.9.6 !-pentadecan one

Use of imidazol-1-yl compounds of the general formula I ##STR1## wherein R.sup.1 denotes lower alkyl or hydrogen;

Method of treating colon disturbances with pharmaceutical compositions

Ring-contracted N-demethyl-N-isopropylerythromycin A derivatives with gastrointestinally effective motilin-agonistic properties, a method for preparing such compounds, and pharmaceutical compositions containing them.

4,13-dioxabicyclo[8.2.1]tridecenone compounds and pharmaceutical

Pharmacologically active compounds corresponding to the general formula I: ##STR1## wherein m represents 1-4,

Phenyalkylaminoalkyl compounds and pharmaceutical compositions

Pharmacologically active compounds corresponding to the general formula I ##STR1## in which R.sup.1 represents hydrogen, a lower alkyl or cycloalkyl-alkyl group or an optionally substituted phenyl-lower alkyl group,

6-oxoazepinoindole compounds, and pharmaceutical compositions containing

Pharmacologically active compounds corresponding to the formula I ##STR1## in which n represents 2-5,

Alkylaminoalkylamine and ether compounds, processes and intermediates

Flavone-3-carboxylic acid compounds corresponding to the Formula I: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 represent hydrogen, lower alkyl, halogen, hydroxy, or etherified or esterified hydroxy, and Z-R.sup.6 stands for a basically substituted alkoxy or amino group, as well as processes and intermediate products for their production. The compounds exhibit inflammation-inhibiting pharmacological activity.

3-flavone carboxylic acid compounds

Growing community of inventors

Lehrte/Ahlten, Germany

Ulf Preuschoff